

# Jee Hyun Kim

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3633041/publications.pdf>

Version: 2024-02-01

163  
papers

4,165  
citations

236925

25  
h-index

138484

58  
g-index

170  
all docs

170  
docs citations

170  
times ranked

6380  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Estrogen Receptor Expression Level and Hormonal Therapy on Prognosis of Early Breast Cancer. <i>Cancer Research and Treatment</i> , 2022, 54, 1081-1090.	3.0	6
2	Cetuximab resistance induced by hepatocyte growth factor is overcome by MET inhibition in KRAS, NRAS, and BRAF wild-type colorectal cancers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2022, 148, 2995-3005.	2.5	5
3	Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group. <i>Cancer Research and Treatment</i> , 2022, 54, 1-9.	3.0	9
4	Clinical characteristics and disease course of splanchnic vein thrombosis in gastrointestinal cancers: A prospective cohort study. <i>PLoS ONE</i> , 2022, 17, e0261671.	2.5	4
5	Exploratory analysis of biomarkers associated with clinical outcomes from the study of palbociclib plus endocrine therapy in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer. <i>Breast</i> , 2022, 62, 52-60.	2.2	13
6	Abstract P1-18-32: A nationwide real-world study for evaluation of efficacy and safety of T-DM1 in patients with HER2-positive locally-advanced unresectable or metastatic breast cancer in Korea (KCSG) Tj ETQq0 0 0.9 BT /Overlock 10 T	0.9	0
7	Abstract P1-16-01: Pemetrexed plus vinorelbine versus vinorelbine monotherapy in patients with metastatic breast cancer: A randomized, open-label, multicenter, phase II trial (KCSG-BR15-17). <i>Cancer Research</i> , 2022, 82, P1-16-01-P1-16-01.	0.9	0
8	Abstract P5-16-03: Phase II study of trastuzumab biosimilar (Herzuma <sup>®</sup> ) plus gedatolisib in patients with HER-2 positive metastatic breast cancer who progressed after 2 or more HER-2 directed chemotherapy (BR 18-13, KM-10A): Interim analysis. <i>Cancer Research</i> , 2022, 82, P5-16-03-P5-16-03.	0.9	0
9	Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer. <i>New England Journal of Medicine</i> , 2022, 386, 1143-1154.	27.0	474
10	Treatment patterns of thrombopoietin receptor agonists among adults with primary immune thrombocytopenia: A Korean nationwide population-based study. <i>Thrombosis Research</i> , 2022, 213, 114-118.	1.7	0
11	The impact of systematic assessment for adverse events on unscheduled hospital utilization in patients receiving neoadjuvant or adjuvant chemotherapy: A retrospective multicenter study. <i>Cancer Medicine</i> , 2022, 11, 705-714.	2.8	1
12	Performance of clinician prediction of survival in oncology outpatients with advanced cancer. <i>PLoS ONE</i> , 2022, 17, e0267467.	2.5	4
13	Effectiveness of oral fluoropyrimidine monotherapy as adjuvant chemotherapy for high-risk stage II colon cancer. <i>Annals of Surgical Treatment and Research</i> , 2022, 102, 271.	1.0	3
14	Phase 1b/2 study of GX-17 plus pembrolizumab in patients with refractory or recurrent (R/R) metastatic triple-negative breast cancer (mTNBC): The KEYNOTE-899 Study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 1081-1081.	1.6	3
15	A phase IB/II study of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer (KCSG BR18-16).. <i>Journal of Clinical Oncology</i> , 2022, 40, 1098-1098.	1.6	1
16	Clinical Application of Next-Generation Sequencing in Patients With Breast Cancer: Real-World Data. <i>Journal of Breast Cancer</i> , 2022, 25, 366.	1.9	8
17	Response Rate and Safety of a Neoadjuvant Pertuzumab, Atezolizumab, Docetaxel, and Trastuzumab Regimen for Patients With ERBB2-Positive Stage II/III Breast Cancer. <i>JAMA Oncology</i> , 2022, 8, 1271.	7.1	15
18	A Phase Ib Study of Alpelisib or Buparlisib Combined with Tamoxifen Plus Goserelin in Premenopausal Women with HR-Positive HER2-Negative Advanced Breast Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 408-417.	7.0	21

#	ARTICLE	IF	CITATIONS
19	Pneumocystis jirovecii pneumonia in diffuse large B-cell Lymphoma treated with R-CHOP. Mycoses, 2021, 64, 60-65.	4.0	7
20	Palbociclib Plus Fulvestrant in Korean Patients from PALOMA-3 With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer. Journal of Breast Cancer, 2021, 24, 97.	1.9	3
21	A target-mediated drug disposition population pharmacokinetic model of GC1118, a novel anti-EGFR antibody, in patients with solid tumors. Clinical and Translational Science, 2021, 14, 990-1001.	3.1	0
22	Prevalence and Predictive Factors for Upfront Dose Reduction of the First Cycle of First-Line Chemotherapy in Older Adults with Metastatic Solid Cancer: Korean Cancer Study Group (KCSG) Multicenter Study. Cancers, 2021, 13, 331.	3.7	4
23	A single-arm feasibility study of gradual dose de-escalation of antiemetic dexamethasone for older patients receiving chemotherapy. Journal of Geriatric Oncology, 2021, 12, 922-929.	1.0	1
24	Randomised Phase 1b/2 trial of tepotinib vs sorafenib in Asian patients with advanced hepatocellular carcinoma with MET overexpression. British Journal of Cancer, 2021, 125, 200-208.	6.4	22
25	A phase I dose-escalation and expansion study of JPI-547, a dual inhibitor of PARP/tankyrase in patients with advanced solid tumors.. Journal of Clinical Oncology, 2021, 39, 3113-3113.	1.6	3
26	Multicenter study for brain metastasis from breast cancer in Korea: The significance of molecular subtype (Korean Radiation Oncology Group 1612).. Journal of Clinical Oncology, 2021, 39, e14008-e14008.	1.6	0
27	Prognostic implications of regression of metastatic axillary lymph nodes after neoadjuvant chemotherapy in patients with breast cancer. Scientific Reports, 2021, 11, 12128.	3.3	5
28	Tissue pharmacokinetics of DHP107, a novel lipid-based oral formulation of paclitaxel, in mice and patients by positron emission tomography. Clinical and Translational Science, 2021, 14, 1747-1755.	3.1	4
29	Open versus laparoscopic surgery for mid or low rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): 10-year follow-up of an open-label, non-inferiority, randomised controlled trial. The Lancet Gastroenterology and Hepatology, 2021, 6, 569-577.	8.1	50
30	A Prognostic Model to Facilitate Palliative Care Referral in Oncology Outpatients. Cancer Research and Treatment, 2021, , .	3.0	1
31	Implications of Tamoxifen Resistance in Palbociclib Efficacy for Patients with Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Subgroup Analyses of KCSG-BR15-10 (YoungPEARL). Cancer Research and Treatment, 2021, 53, 695-702.	3.0	1
32	A Real-world Efficacy of Nab-paclitaxel Monotherapy in Metastatic Breast Cancer. Cancer Research and Treatment, 2021, , .	3.0	4
33	A randomised phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy. European Journal of Cancer, 2021, 154, 288-295.	2.8	26
34	Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer. Cancer Research and Treatment, 2021, 53, 1096-1103.	3.0	9
35	R-MPV followed by high-dose chemotherapy with thiotepa-based and autologous stem cell transplantation for newly diagnosed primary central nervous system lymphoma: a single-center experience. Blood Research, 2021, 56, 285-292.	1.3	3
36	Amphiregulin can predict treatment resistance to palliative first-line cetuximab plus FOLFIRI chemotherapy in patients with RAS wild-type metastatic colorectal cancer. Scientific Reports, 2021, 11, 23803.	3.3	4

#	ARTICLE	IF	CITATIONS
37	Awareness of Doctors's Shared Decision-Making in Life-Sustaining Care Decisions. <i>The Korean Journal of Hospice and Palliative Care</i> , 2021, 24, 204-213.	0.7	1
38	Conversion Surgery in Metastatic Gastric Cancer and Cancer Dormancy as a Prognostic Biomarker. <i>Cancers</i> , 2020, 12, 86.	3.7	11
39	Genomic profiling of multiple breast cancer reveals inter-lesional heterogeneity. <i>British Journal of Cancer</i> , 2020, 122, 697-704.	6.4	6
40	Polypharmacy, Inappropriate Medication Use, and Drug Interactions in Older Korean Patients with Cancer Receiving First-Line Palliative Chemotherapy. <i>Oncologist</i> , 2020, 25, e502-e511.	3.7	32
41	Symptom burden and characteristics of patients who die in the acute palliative care unit of a tertiary cancer center. <i>Annals of Palliative Medicine</i> , 2020, 9, 216-223.	1.2	4
42	Identifying germline APOBEC3B deletion and immune phenotype in Korean patients with operable breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 697-704.	2.5	3
43	PI3K-targeting strategy using alpelisib to enhance the antitumor effect of paclitaxel in human gastric cancer. <i>Scientific Reports</i> , 2020, 10, 12308.	3.3	20
44	Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 743-753.	2.5	4
45	Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase II Trial (KCSG-BR 15-10). <i>Cancers</i> , 2020, 12, 3265.	3.7	9
46	Conversion surgery after cetuximab or bevacizumab plus FOLFIRI chemotherapy in colorectal cancer patients with liver- and/or lung-limited metastases. <i>Journal of Cancer Research and Clinical Oncology</i> , 2020, 146, 2399-2410.	2.5	10
47	Regorafenib in patients with advanced Child-Pugh B hepatocellular carcinoma: A multicentre retrospective study. <i>Liver International</i> , 2020, 40, 2544-2552.	3.9	32
48	Randomized, phase II trial to evaluate the efficacy and safety of atezolizumab plus capecitabine adjuvant therapy compared to capecitabine monotherapy for triple receptor-negative breast cancer (TNBC) with residual invasive cancer after neoadjuvant chemotherapy (MIRINAE trial, KCSG-BR18-21).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS597-TPS597.	1.6	6
49	Endometrial profilin 1: a key player in embryo-endometrial crosstalk. <i>Clinical and Experimental Reproductive Medicine</i> , 2020, 47, 114-121.	1.5	5
50	A randomized phase II study of oxaliplatin/5-FU (mFOLFOX) versus irinotecan/5-FU (mFOLFIRI) chemotherapy in locally advanced or metastatic biliary tract cancer refractory to first-line gemcitabine/cisplatin chemotherapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4603-4603.	1.6	5
51	Preliminary safety and efficacy of GX-17, a long-acting interleukin-7, in combination with pembrolizumab in patients with refractory or recurrent metastatic triple negative breast cancer (mTNBC): Dose escalation period of Phase Ib/II study (KEYNOTE-899).. <i>Journal of Clinical Oncology</i> , 2020, 38, 1072-1072.	1.6	3
52	Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11). <i>Breast Cancer Research and Treatment</i> , 2019, 178, 367-377.	2.5	3
53	Phase I Dose-Finding Study of OPB-111077, a Novel STAT3 Inhibitor, in Patients with Advanced Hepatocellular Carcinoma. <i>Cancer Research and Treatment</i> , 2019, 51, 510-518.	3.0	39
54	Changes in Biomarker Status in Metastatic Breast Cancer and Their Prognostic Value. <i>Journal of Breast Cancer</i> , 2019, 22, 439.	1.9	19

#	ARTICLE	IF	CITATIONS
55	Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1750-1759.	10.7	86
56	Prognostic implication of ABC transporters and cancer stem cell markers in patients with stage III colon cancer receiving adjuvant FOLFOX chemotherapy. <i>Oncology Letters</i> , 2019, 17, 5572-5580.	1.8	9
57	Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG) Tj ETQq1 1 0.784314 5rgBT /Overl	0.92	5
58	Clinical characteristics and outcomes of patients enrolled in clinical trials compared with those of patients outside clinical trials in advanced gastric cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2019, 15, 158-165.	1.1	3
59	Serum biomarkers for predicting overall survival and early mortality in older patients with metastatic solid tumors. <i>Journal of Geriatric Oncology</i> , 2019, 10, 749-756.	1.0	13
60	Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients. <i>International Journal of Cancer</i> , 2019, 145, 1669-1678.	5.1	14
61	Identification of a potentially avoidable cardiopulmonary resuscitation in hematology and oncology wards. <i>BMC Palliative Care</i> , 2019, 18, 93.	1.8	3
62	Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement. <i>Cells</i> , 2019, 8, 1538.	4.1	7
63	Acute pulmonary thromboembolism caused by factor V Leiden mutation in South Korea. <i>Medicine (United States)</i> , 2019, 98, e16318.	1.0	1
64	Incidence and predictors of venous thromboembolism in medically ill hospitalized elderly cancer patients: a prospective observational study. <i>Supportive Care in Cancer</i> , 2019, 27, 2507-2515.	2.2	8
65	A randomized phase II study of palbociclib plus exemestane with GNRH agonist versus capecitabine in premenopausal women with hormone receptor-positive metastatic breast cancer (KCSG-BR 15-10.) Tj ETQq1 1 0.784314 5rgBT /Overl	0.784314	5
66	Challenges and insights of early oncology drug development in the Asia-Pacific region: introduction of phase I oncology clinical trial center and experience sharing for early clinical trials in Seoul National University Hospital, Korea. <i>Chinese Clinical Oncology</i> , 2019, 8, 27-27.	1.2	2
67	Contralateral Breast Cancer and Ipsilateral Breast Tumor Recurrence in <i>BRCA1/2</i> Carriers and Non-Carriers at High-Risk of Hereditary Breast Cancer. <i>Journal of Breast Cancer</i> , 2019, 22, 587.	1.9	9
68	Randomized Open Label Phase III Trial of Irinotecan Plus Capecitabine versus Capecitabine Monotherapy in Patients with Metastatic Breast Cancer Previously Treated with Anthracycline and Taxane: PROCEED Trial (KCSG BR 11-01). <i>Cancer Research and Treatment</i> , 2019, 51, 43-52.	3.0	34
69	Prospective Validation of The Korean Cancer Study Group Geriatric Score (KG)-7, a Novel Geriatric Screening Tool, in Older Patients with Advanced Cancer Undergoing First-line Palliative Chemotherapy. <i>Cancer Research and Treatment</i> , 2019, 51, 1249-1256.	3.0	5
70	Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer. <i>Cancer Research and Treatment</i> , 2019, 51, 1086-1097.	3.0	59
71	Symptom burden and characteristics of patients who die in the acute palliative care unit of a tertiary cancer center.. <i>Journal of Clinical Oncology</i> , 2019, 37, 53-53.	1.6	0
72	A phase II trial of S-1 and oxaliplatin in patients with advanced hepatocellular carcinoma. <i>BMC Cancer</i> , 2018, 18, 252.	2.6	7

#	ARTICLE	IF	CITATIONS
73	A Novel Prognostic Nomogram for Predicting Risks of Distant Failure in Patients with Invasive Breast Cancer Following Postoperative Adjuvant Radiotherapy. <i>Cancer Research and Treatment</i> , 2018, 50, 1140-1148.	3.0	12
74	A population-based outcomes study of patients with metastatic gastric cancer receiving second-line chemotherapy: A nationwide health insurance database study. <i>PLoS ONE</i> , 2018, 13, e0205853.	2.5	10
75	BGJ398, A Pan-FGFR Inhibitor, Overcomes Paclitaxel Resistance in Urothelial Carcinoma with FGFR1 Overexpression. <i>International Journal of Molecular Sciences</i> , 2018, 19, 3164.	4.1	17
76	Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study). <i>European Journal of Cancer</i> , 2018, 103, 127-136.	2.8	10
77	Analysis of survival outcomes based on molecular subtypes in breast cancer brain metastases: A single institutional cohort. <i>Breast Journal</i> , 2018, 24, 920-926.	1.0	16
78	Impact of Tumor Regression Grade as a Major Prognostic Factor in Locally Advanced Rectal Cancer after Neoadjuvant Chemoradiotherapy: A Proposal for a Modified Staging System. <i>Cancers</i> , 2018, 10, 319.	3.7	45
79	Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study. <i>PLoS ONE</i> , 2018, 13, e0198544.	2.5	21
80	Predicting cumulative incidence of adverse events in older patients with cancer undergoing first-line palliative chemotherapy: Korean Cancer Study Group (KCSG) multicentre prospective study. <i>British Journal of Cancer</i> , 2018, 118, 1169-1175.	6.4	25
81	Comparative analysis between combination and single-agent chemotherapy for elderly patients with advanced non-small cell lung cancer: A nationwide population-based outcome study. <i>Lung Cancer</i> , 2018, 122, 88-93.	2.0	6
82	Microinvasive Carcinoma versus Ductal Carcinoma <i>in Situ</i> : A Comparison of Clinicopathological Features and Clinical Outcomes. <i>Journal of Breast Cancer</i> , 2018, 21, 197.	1.9	46
83	Survival Benefit of Surgical Removal of Primary Tumor in Patients With Stage IV Breast Cancer. <i>Clinical Breast Cancer</i> , 2018, 18, e1037-e1044.	2.4	6
84	Phase I dose-finding study of OPB-111077, a novel STAT3 inhibitor, in patients with advanced hepatocellular carcinoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 4078-4078.	1.6	3
85	Role of HER2 copy number amplification and PI3K pathway as a biomarker for patients with HER2+ MBC treating with Pozitotinib, pan-HER TKI.. <i>Journal of Clinical Oncology</i> , 2018, 36, e13009-e13009.	1.6	1
86	Experiences and Opinions Related to End-of-Life Discussion: From Oncologists' and Resident Physicians' Perspectives. <i>Cancer Research and Treatment</i> , 2018, 50, 614-623.	3.0	23
87	Negative Conversion of Progesterone Receptor Status after Primary Systemic Therapy Is Associated with Poor Clinical Outcome in Patients with Breast Cancer. <i>Cancer Research and Treatment</i> , 2018, 50, 1418-1432.	3.0	19
88	Liver and/or lung metastasectomy after cetuximab or bevacizumab+FOLFIRI chemotherapy in patients (pts) with metastatic colorectal cancer (mCRC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 843-843.	1.6	0
89	Quality of life(QoL) outcomes including neuropathy associated scale (FACT-T) from a phase II, multicenter, randomized trial of eribulin plus gemcitabine(EG) versus paclitaxel plus gemcitabine(PG) as first-line chemotherapy for human epidermal growth factor receptor 2 (HER2)- negative metastatic breast cancer(MBC): Korean Cancer Study Group trial (KCSG BR13-11).. <i>Journal of Clinical Oncology</i> , 2018, 36, 10117-10117.	1.6	0
90	Prognostic benefit of taking statin and/or metformin in elderly patients with advanced non-small cell lung cancer: A nationwide population-based epidemiologic study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 10045-10045.	1.6	1

#	ARTICLE	IF	CITATIONS
91	Prognostic significance of centromere 17 copy number gain in breast cancer depends on breast cancer subtype. <i>Human Pathology</i> , 2017, 61, 111-120.	2.0	10
92	Efficacy and Safety of FOLFIRI Regimen in Elderly Versus Nonelderly Patients with Metastatic Colorectal or Gastric Cancer. <i>Oncologist</i> , 2017, 22, 293-303.	3.7	5
93	Epidemiology and management of primary immune thrombocytopenia: A nationwide population-based study in Korea. <i>Thrombosis Research</i> , 2017, 155, 86-91.	1.7	46
94	Prognostic value of p21-activated kinase 4 in resected pancreatic cancer. <i>Apmis</i> , 2017, 125, 699-707.	2.0	12
95	Failure patterns according to molecular subtype in patients with invasive breast cancer following postoperative adjuvant radiotherapy: long-term outcomes in contemporary clinical practice. <i>Breast Cancer Research and Treatment</i> , 2017, 163, 555-563.	2.5	18
96	Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer. <i>European Journal of Cancer</i> , 2017, 86, 385-393.	2.8	23
97	Total lesion glycolysis (TLG) as an imaging biomarker in metastatic colorectal cancer patients treated with regorafenib. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017, 44, 757-764.	6.4	27
98	EGFR or HER2 inhibition modulates the tumor microenvironment by suppression of PD-L1 and cytokines release. <i>Oncotarget</i> , 2017, 8, 63901-63910.	1.8	30
99	Treatment Patterns and Outcomes in Elderly Patients with Metastatic Breast Cancer: A Multicenter Retrospective Study. <i>Journal of Breast Cancer</i> , 2017, 20, 368.	1.9	11
100	PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy: Safety and Efficacy in Asian Patients. <i>Journal of Global Oncology</i> , 2017, 3, 289-303.	0.5	94
101	Predicting cumulative incidence of chemotherapy toxicity in older patients with cancer: Korean Cancer Study Group prospective cohort study (KCSG) PC 13-09.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21539-e21539.	1.6	1
102	Post-bevacizumab Clinical Outcomes and the Impact of Early Discontinuation of Bevacizumab in Patients with Recurrent Malignant Glioma. <i>Cancer Research and Treatment</i> , 2017, 49, 129-140.	3.0	5
103	Feasibility and Efficacy of Eribulin Mesilate in Korean Patients with Metastatic Breast Cancer: Korean Multi-center Phase IV Clinical Study Results. <i>Cancer Research and Treatment</i> , 2017, 49, 423-429.	3.0	7
104	Bilateral Salpingo-oophorectomy Compared to Gonadotropin-Releasing Hormone Agonists in Premenopausal Hormone Receptor-Positive Metastatic Breast Cancer Patients Treated with Aromatase Inhibitors. <i>Cancer Research and Treatment</i> , 2017, 49, 1153-1163.	3.0	9
105	Use of a Comprehensive Geriatric Assessment to Predict Short-Term Postoperative Outcome in Elderly Patients With Colorectal Cancer. <i>Annals of Coloproctology</i> , 2016, 32, 161.	2.0	44
106	Expression of breast cancer stem cell markers as predictors of prognosis and response to trastuzumab in HER2-positive breast cancer. <i>British Journal of Cancer</i> , 2016, 114, 1109-1116.	6.4	37
107	Preoperative chemoradiotherapy for elderly patients with locally advanced rectal cancer—a real-world outcome study. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 1108-1117.	1.3	16
108	Challenges in supportive cancer care: perspectives from the Asia Pacific and Middle East. <i>Supportive Care in Cancer</i> , 2016, 24, 4479-4481.	2.2	11

#	ARTICLE	IF	CITATIONS
109	Prognostic implications of immunosuppressive protein expression in tumors as well as immune cell infiltration within the tumor microenvironment in gastric cancer. <i>Gastric Cancer</i> , 2016, 19, 42-52.	5.3	230
110	Population-based outcomes research on treatment patterns and impact of chemotherapy in older patients with metastatic gastric cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 687-697.	2.5	12
111	A randomized, multicenter, phase II/III study to determine the optimal dose and to evaluate the efficacy and safety of pegteogristim (GCPGC) on chemotherapy-induced neutropenia compared to pegfilgrastim in breast cancer patients: KCSG PC10-09. <i>Supportive Care in Cancer</i> , 2016, 24, 1709-1717.	2.2	19
112	Amphiregulin confers trastuzumab resistance via AKT and ERK activation in HER2-positive breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2016, 142, 157-165.	2.5	27
113	Multidimensional Geriatric Prognostic Index, Based on a Geriatric Assessment, for Long-Term Survival in Older Adults in Korea. <i>PLoS ONE</i> , 2016, 11, e0147032.	2.5	12
114	The Expression of Carbonic Anhydrase (CA) IX/XII and Lymph Node Metastasis in Early Breast Cancer. <i>Cancer Research and Treatment</i> , 2016, 48, 125-132.	3.0	8
115	Phase I Study of CKD-516, a Novel Vascular Disrupting Agent, in Patients with Advanced Solid Tumors. <i>Cancer Research and Treatment</i> , 2016, 48, 28-36.	3.0	20
116	Antitumor Activity of HM781-36B, alone or in Combination with Chemotherapeutic Agents, in Colorectal Cancer Cells. <i>Cancer Research and Treatment</i> , 2016, 48, 355-364.	3.0	7
117	Prospective Study on the Incidence of Postoperative Venous Thromboembolism in Korean Patients with Colorectal Cancer. <i>Cancer Research and Treatment</i> , 2016, 48, 978-989.	3.0	16
118	Prognostic Value of Axillary Nodal Ratio after Neoadjuvant Chemotherapy of Doxorubicin/Cyclophosphamide Followed by Docetaxel in Breast Cancer: A Multicenter Retrospective Cohort Study. <i>Cancer Research and Treatment</i> , 2016, 48, 1373-1381.	3.0	9
119	Efficacy and safety of FOLFIRI regimen in elderly versus nonelderly patients with advanced colorectal and gastric cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 701-701.	1.6	0
120	Clinical outcomes of patients enrolled in clinical trial compared with patients outside clinical trial in advanced gastric cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, 21-21.	1.6	0
121	Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer. <i>Cancer Research and Treatment</i> , 2016, 48, 499-507.	3.0	0
122	Effect of Smad3/4 on chemotherapeutic drug sensitivity in colorectal cancer cells. <i>Oncology Reports</i> , 2015, 33, 185-192.	2.6	14
123	Potential Prognostic Value of Histone Deacetylase 6 and Acetylated Heat-Shock Protein 90 in Early-Stage Breast Cancer. <i>Journal of Breast Cancer</i> , 2015, 18, 249.	1.9	13
124	Efficacy of Random-start Controlled Ovarian Stimulation in Cancer Patients. <i>Journal of Korean Medical Science</i> , 2015, 30, 290.	2.5	55
125	Impact of Intratumoral Expression Levels of Fluoropyrimidine-Metabolizing Enzymes on Treatment Outcomes of Adjuvant S-1 Therapy in Gastric Cancer. <i>PLoS ONE</i> , 2015, 10, e0120324.	2.5	7
126	Impact of Postoperative Chemoradiotherapy versus Chemotherapy Alone on Recurrence and Survival in Patients with Stage II and III Upper Rectal Cancer: A Propensity Score-Matched Analysis. <i>PLoS ONE</i> , 2015, 10, e0123657.	2.5	6



#	ARTICLE	IF	CITATIONS
127	A Novel Geriatric Screening Tool in Older Patients with Cancer: The Korean Cancer Study Group Geriatric Score (KG)-7. PLoS ONE, 2015, 10, e0138304.	2.5	10
128	Prevalence and outcomes of extrahepatic primary malignancy associated with Hepatocellular Carcinoma in a Korean population. BMC Cancer, 2015, 15, 146.	2.6	6
129	Quality of life (QoL) in metastatic breast cancer patients with maintenance paclitaxel plus gemcitabine (PG) chemotherapy: results from phase III, multicenter, randomized trial of maintenance chemotherapy versus observation (KCSG-BR07-02). Breast Cancer Research and Treatment, 2015, 152, 77-85.	2.5	17
130	Impact of Lymph Node Ratio on Oncologic Outcomes in ypStage III Rectal Cancer Patients Treated with Neoadjuvant Chemoradiotherapy followed by Total Mesorectal Excision, and Postoperative Adjuvant Chemotherapy. PLoS ONE, 2015, 10, e0138728.	2.5	14
131	Clinical Implication of Anti-Angiogenic Effect of Regorafenib in Metastatic Colorectal Cancer. PLoS ONE, 2015, 10, e0145004.	2.5	20
132	Five-Year Follow-up Study of Monoclonal Gammopathy of Undetermined Significance in a Korean Elderly Urban Cohort. Cancer Research and Treatment, 2015, 47, 215-220.	3.0	6
133	p21-Activated Kinase 4 (PAK4) as a Predictive Marker of Gemcitabine Sensitivity in Pancreatic Cancer Cell Lines. Cancer Research and Treatment, 2015, 47, 501-508.	3.0	29
134	Salvage Treatment with Intracerebrospinal Fluid Thiotepa in Patients with Leptomeningeal Metastasis After Failure of Methotrexate-based Treatment. Anticancer Research, 2015, 35, 5631-8.	1.1	4
135	Actinomyces-like organisms in cervical smears: the association with intrauterine device and pelvic inflammatory diseases. Obstetrics and Gynecology Science, 2014, 57, 393.	1.6	14
136	Histone Acetylation Level and Histone Acetyltransferase/Deacetylase Activity in Ejaculated Sperm from Normozoospermic Men. Yonsei Medical Journal, 2014, 55, 1333.	2.2	26
137	Prevalence and Risk Factors for Iron Deficiency Anemia in the Korean Population: Results of the Fifth Korea National Health and Nutrition Examination Survey. Journal of Korean Medical Science, 2014, 29, 224.	2.5	56
138	Anti-Müllerian Hormone Levels in the Follicular Fluid of the Preovulatory Follicle: A Predictor for Oocyte Fertilization and Quality of Embryo. Journal of Korean Medical Science, 2014, 29, 1266.	2.5	23
139	Dose-dependent embryotrophic effect of recombinant granulocyte-macrophage colony-stimulating factor and brain-derived neurotrophic factor in culture medium for mouse preimplantation embryo. Obstetrics and Gynecology Science, 2014, 57, 373.	1.6	4
140	HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer. American Journal of Clinical Pathology, 2014, 142, 755-766.	0.7	109
141	Nomogram to predict ongoing pregnancy using age of women and serum biomarkers after in vitro fertilization cycles. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2014, 172, 65-69.	1.1	12
142	High EGFR gene copy number predicts poor outcome in triple-negative breast cancer. Modern Pathology, 2014, 27, 1212-1222.	5.5	220
143	Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncology, The, 2014, 15, 1245-1253.	10.7	336
144	Gastric cancer with initial bone metastasis: A distinct group of diseases with poor prognosis. European Journal of Cancer, 2014, 50, 2810-2821.	2.8	33

#	ARTICLE	IF	CITATIONS
145	Can intracytoplasmic sperm injection prevent total fertilization failure and enhance embryo quality in patients with non-male factor infertility?. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2014, 178, 188-191.	1.1	34
146	Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial. <i>Lancet Oncology</i> , The, 2014, 15, 767-774.	10.7	713
147	Successful Conservative Management of Ruptured Ovarian Cysts with Hemoperitoneum in Healthy Women. <i>PLoS ONE</i> , 2014, 9, e911171.	2.5	26
148	Diagnostic Accuracy of Computed Tomography and Magnetic Resonance Imaging Obtained after Neoadjuvant Chemoradiotherapy in Predicting the Local Tumor Stage and Circumferential Resection Margin Status of Rectal Cancer. <i>Journal of the Korean Society of Radiology</i> , 2014, 70, 123.	0.2	1
149	CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials. <i>Epidemiology and Health</i> , 2014, 36, e2014029.	1.9	23
150	Magnetic Resonance Imaging Factors Predicting Re-excision in Breast Cancer Patients Having Undergone Conserving Therapy. <i>Journal of the Korean Society of Magnetic Resonance in Medicine</i> , 2014, 18, 133.	0.1	3
151	ABCB1 polymorphism as a prognostic factor in breast cancer patients with neoadjuvant chemotherapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 1038-1038.	1.6	0
152	Treatment Strategy for Elderly Patients with Metastatic Colorectal Cancer: A Review of the Systemic Chemotherapy Options. <i>Current Colorectal Cancer Reports</i> , 2013, 9, 213-222.	0.5	1
153	Phase I study to evaluate the safety and to assess the food effect of HM781-36B, a novel pan-HER inhibitor continuously given in patients with advanced solid tumors.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2565-2565.	1.6	1
154	A prospective study on the incidence of postoperative venous thromboembolism in Korean gastric cancer patients: An inquiry into the application of western guidelines to Asian cancer patients.. <i>Journal of Clinical Oncology</i> , 2013, 31, e15129-e15129.	1.6	0
155	Post-bevacizumab treatment and clinical outcomes in recurrent malignant glioma.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2098-2098.	1.6	0
156	Empty follicle syndrome. <i>Clinical and Experimental Reproductive Medicine</i> , 2012, 39, 132.	1.5	27
157	Serum biomarkers for predicting pregnancy outcome in women undergoing IVF: human chorionic gonadotropin, progesterone, and inhibin A level at 11 days post-ET. <i>Clinical and Experimental Reproductive Medicine</i> , 2012, 39, 28.	1.5	13
158	Individualized Tumor Response Testing for Prediction of Response to Paclitaxel and Cisplatin Chemotherapy in Patients with Advanced Gastric Cancer. <i>Journal of Korean Medical Science</i> , 2010, 25, 684.	2.5	9
159	Radiation-induced Pulmonary Toxicity and Related Risk Factors in Breast Cancer. <i>Journal of Breast Cancer</i> , 2009, 12, 67.	1.9	7
160	Artificial nutrition and hydration in terminal cancer patients: the real and the ideal. <i>Supportive Care in Cancer</i> , 2007, 15, 631-636.	2.2	18
161	Randomized phase II study of gemcitabine plus cisplatin versus etoposide plus cisplatin for the treatment of locally advanced or metastatic non-small cell lung cancer: Korean Cancer Study Group experience. <i>Lung Cancer</i> , 2006, 52, 75-81.	2.0	11
162	Graft-Versus-Host Disease after Allogeneic Hematopoietic Stem Cell Transplantation with Non-Myeloablative Conditioning: Experiences at a Single Center. <i>The Korean Journal of Hematology</i> , 2006, 41, 92.	0.7	0

#	ARTICLE	IF	CITATIONS
163	Simple Partial Status Epilepticus Localized by Single-Photon Emission Computed Tomography Subtraction in Chronic Cerebral Paragonimiasis. Journal of Neuroimaging, 2004, 14, 365-368.	2.0	10